The transplantation donation process in the Centro de Investigaciones Medico Quirurgicas of Cuba: 1999-2002.

Transplant Proc

Centro de Investigaciones Medico Quirurgicas, Unidad de Cuidados Intensivos, Servicio de Trasplantes, Ciudad Habana, Cuba.

Published: August 2003

Objective: In 1998 in the Centro de Investigaciones Medico Quirurgicas the Transplant Coordination Office (TCO) was created, with the aim to organize a system to support a hepatic transplantation program. This organization, which changed the transplantation-donation process not only in our center but in the whole country, is described in this article.

Method: The files of donors generated in our hospital were studied together with the transplant coordination records, from 1999 till the first half of 2002.

Results: In the period studied, 21 potential donors were diagnosed with brain death, yielding a donation rate of 71.4%. Brain death was most frequently caused by vascular brain disease; however, in the realized donor group, the cranioencephalic trauma predominated. The typical donor was a man of average age 39.2 years (range, 18-86 years). Among the potential donors, 24% were excluded based on medical criteria, and 5% due to family objections. Forty liver transplantation were performed in 36 patients including 1 liver-kidney simultaneous procedure. The principal etiologies for transplant included hepatitis C virus cirrhosis, 22%; alcoholic, 19%; and acute hepatic failure, 13%. Kidney transplantations were performed in 70 patients, including 41 from cadaveric donors (53.6%) and 29 from living related donors (41.4%). In 2001, a pancreas-kidney transplantation program was started.

Conclusion: The creation of the TCO has been of paramount importance to optimize transplantation program functions.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0041-1345(03)00696-1DOI Listing

Publication Analysis

Top Keywords

transplantation program
12
centro investigaciones
8
investigaciones medico
8
medico quirurgicas
8
transplant coordination
8
potential donors
8
brain death
8
performed patients
8
patients including
8
transplantation
5

Similar Publications

Immune suppression sustained allograft acceptance requires PD1 inhibition of CD8+ T cells.

J Immunol

January 2025

Division of Infectious Diseases, Center for Inflammation and Tolerance, Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, OH, United States.

Organ transplant recipients require continual immune-suppressive therapies to sustain allograft acceptance. Although medication nonadherence is a major cause of rejection, the mechanisms responsible for graft loss in this clinically relevant context among individuals with preceding graft acceptance remain uncertain. Here, we demonstrate that skin allograft acceptance in mice maintained with clinically relevant immune-suppressive therapies, tacrolimus and mycophenolate, sensitizes hypofunctional PD1hi graft-specific CD8+ T cells.

View Article and Find Full Text PDF

While immunotherapy has shown some efficacy in lung adenocarcinoma (LUAD) patients, many respond only partially or not at all. One limitation in improving outcomes is the lack of a complete understanding of immune checkpoint regulation. Here, we investigated a possible link between an environmental chemical receptor implicated in lung cancer and immune regulation, the AhR, a known but counterintuitive mediator of immunosuppression (interferon (IFN)-γ), and regulation of two immune checkpoints (PD-L1 and IDO).

View Article and Find Full Text PDF

Individualized Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administration in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Nurse's Role.

J Infus Nurs

March 2025

Author Affiliations: Takeda Development Center Americas, Inc., Cambridge, Massachusetts (Kim Duff); IQVIA Clinical Research Organization, Milan, Italy (Arianna Soresini); IQVIA Clinical Research Organization, Cambridge, Massachusetts (Nancy Wolf* and Alane Fairchild); IQVIA Clinical Research Organization, Ankara, Turkey (Şükran Altan**); IQVIA Clinical Research Organization, Mexico City, Mexico (Wendy Bencomo); University Clinical Center of Serbia, Belgrade, Serbia (Ivana Ivankovic); University Health Network, University of Toronto, Toronto, Ontario, Canada (Evelyn Sarpong); IQVIA Clinical Research Organization, Warsaw, Poland (Anna Kuczkowska).

Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% offers potential improvements in patient independence and tolerability versus intravenous immunoglobulin (IVIG) when used for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). fSCIG 10% also requires less frequent infusions and fewer infusion sites than conventional subcutaneous immunoglobulin (subcutaneous immunoglobulin without hyaluronidase). The ADVANCE-CIDP 1 study demonstrated fSCIG 10% efficacy and safety in preventing CIDP relapse and positive responses from patients in terms of satisfaction and treatment preference.

View Article and Find Full Text PDF

In the randomized, double-blind, phase 3 GRAPHITE study (NCT03657160), anti-αβ integrin antibody vedolizumab showed greater efficacy than placebo for prevention of lower-gastrointestinal (GI) acute graft-versus-host disease (aGVHD) after unrelated allogenic hematopoietic stem cell transplantation (allo-HSCT). This post hoc analysis assessed the efficacy and safety of vedolizumab versus placebo for lower-GI aGVHD prevention in Japanese and non-Japanese patients, when added to standard GVHD prophylaxis (calcineurin inhibitor + methotrexate/mycophenolate mofetil + / - anti-thymocyte globulin [ATG]). The analysis included 35 (18 vedolizumab-treated, 17 placebo-treated) Japanese and 298 (150 vedolizumab-treated, 148 placebo-treated) non-Japanese patients.

View Article and Find Full Text PDF

Healthcare disparities persist in the USA, with Black patients often receiving lower-quality care. Effective doctor-patient communication is crucial for influencing satisfaction, adherence to treatment, and overall health outcomes. This study examined racial disparities in doctor-patient communication, focusing on encounters with Black and White patients recently diagnosed with myelodysplastic neoplasm (MDS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!